Picture of PAVmed logo

PAVM — PAVmed News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

PAVmed Inc expected to post a loss of $1.45 a share - Earnings Preview

* PAVmed Inc  PAVM.OQ   PAVM.O  is expected to show a rise
in
quarterly revenue when it reports  results on August 12 for the
period ending June 30 2024
    * The New York City-based  company is expected to report a
625.0% increase in revenue to $1.204 million from $166 thousand
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for PAVmed Inc is for a loss
of
$1.45 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for PAVmed Inc
is
$6.50​, above​ its last closing price of $0.83. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -1.77       -1.67      -2.62     Missed  -56.6
 Dec. 31 2024  -1.47       -1.89      -1.81     Beat    4.2
 Jan. 1 0001   -2.04       -2.05      -2.40     Missed  -17.1​
 Jan. 1 0001   -2.84       -2.85      -2.10     Beat    26.3
 ​​Mar.        -3.11       -3.10      -2.85     Beat    8.1
 31 2023                                                
 Dec. 31 2022  -3.84       -3.80      -3.45     Beat    9.2​
 Sep. 30 2022  -3.98       -3.97      -4.35     Missed  -9.4
 Jun. 30 2022  -3.45       -3.45      -4.35     Missed  -26.1
 This summary was machine generated August 9 at 23:30 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on PAVmed

See all news